ARS Pharmaceuticals Inc (NASDAQ: SPRY) kicked off on Friday, down -5.80% from the previous trading day, before settling in for the closing price of $10.69. Over the past 52 weeks, SPRY has traded in a range of $10.00-$18.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -2097.86%. With a float of $58.37 million, this company’s outstanding shares have now reached $98.70 million.
ARS Pharmaceuticals Inc (SPRY) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of ARS Pharmaceuticals Inc is 40.94%, while institutional ownership is 62.82%. The most recent insider transaction that took place on Aug 21 ’25, was worth 724,345. In this transaction PRESIDENT AND CEO of this company sold 50,000 shares at a rate of $14.49, taking the stock ownership to the 1,196,494 shares. Before that another transaction happened on Aug 21 ’25, when Company’s Chief Financial Officer sold 12,500 for $15.00, making the entire transaction worth $187,500. This insider now owns 10,042 shares in total.
ARS Pharmaceuticals Inc (SPRY) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.2 earnings per share (EPS), lower than consensus estimate (set at -0.14) by -0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.35 per share during the current fiscal year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
Take a look at ARS Pharmaceuticals Inc’s (SPRY) current performance indicators. Last quarter, stock had a quick ratio of 5.98. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.49, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -0.81 in one year’s time.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
Looking closely at ARS Pharmaceuticals Inc (NASDAQ: SPRY), its last 5-days average volume was 5.17 million, which is a jump from its year-to-date volume of 1.68 million. As of the previous 9 days, the stock’s Stochastic %D was 4.49%.
During the past 100 days, ARS Pharmaceuticals Inc’s (SPRY) raw stochastic average was set at 1.12%, which indicates a significant decrease from 1.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.80 in the past 14 days, which was lower than the 0.81 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.07, while its 200-day Moving Average is $13.81. However, in the short run, ARS Pharmaceuticals Inc’s stock first resistance to watch stands at $10.54. Second resistance stands at $11.01. The third major resistance level sits at $11.30. If the price goes on to break the first support level at $9.78, it is likely to go to the next support level at $9.50. Now, if the price goes above the second support level, the third support stands at $9.03.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Key Stats
The company with the Market Capitalisation of 995.18 million has total of 98,826K Shares Outstanding. Its annual sales at the moment are 89,150 K in contrast with the sum of 8,000 K annual income. Company’s last quarter sales were recorded 15,720 K and last quarter income was -44,880 K.
